Key result
Ticagrelor linked to a 22-second ventricular pause in NSTEMI that resolved after switching to clopidogrel.
Why the study?
Ticagrelor use has been associated with prolonged ventricular pauses, but detailed clinical reports are limited.
Case Report (n=1)
Ticagrelor use may be associated with prolonged ventricular pauses, warranting close monitoring during the first week of therapy.
Answers are grounded in this paper and cite their sources.
May warrant early ECG surveillance with ticagrelor; hypothesis-generating for arrhythmia risk, requiring larger studies before practice change.
CASE: We report a case of a 76-year-old female who presented with non-ST elevation myocardial infarction and developed a 22-second ventricular pause with ticagrelor that did not recur after shifting to clopidogrel. Based on the Naranjo algorithm, the likelihood that our patient's prolonged ventricular pause was due to ticagrelor exposure was probable. CONCLUSION: Ticagrelor use is associated with prolonged ventricular pauses, warranting close monitoring, particularly during the first week of therapy.
No takes yet. Share an insight, caveat, or question.
Rahhal et al. (2021) conducted a case report in non-ST elevation myocardial infarction (n=1). Ticagrelor vs. Clopidogrel was evaluated on Prolonged ventricular pause. Ticagrelor use in a 76-year-old female with NSTEMI was associated with a 22-second ventricular pause that did not recur after switching to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: